Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.
出版年份 2009 全文链接
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started